The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $42.95

Today's change-0.60 -1.38%
Updated July 21 4:02 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $42.95

Today's change-0.60 -1.38%
Updated July 21 4:02 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S down (U.S.)$0.60

Novo Nordisk A/S closed lower Friday, dropping (U.S.)$0.60 or 1.38% to (U.S.)$42.95. Over the last five days, shares are unchanged, but have gained 19.77% over the last year to date. This security has underperformed the S&P 500 by 36.13% during the last year.

Key company metrics

  • Open(U.S.) $42.71
  • Previous close(U.S.) $43.55
  • High(U.S.) $43.07
  • Low(U.S.) $42.50
  • Bid / Ask-- / --
  • YTD % change+19.77%
  • Volume1,233,659
  • Average volume (10-day)1,373,297
  • Average volume (1-month)1,645,970
  • Average volume (3-month)2,062,998
  • 52-week range(U.S.) $30.89 to (U.S.) $57.41
  • Beta0.63
  • Trailing P/E17.88×
  • P/E 1 year forward19.61×
  • Forward PEG2.06×
  • Indicated annual dividend(U.S.) $1.34
  • Dividend yield3.12%
  • Trailing EPS(U.S.) $2.40
Updated July 21 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+34.18%

Based on its net profit margin of 34.18%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.53%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue28,45229,57227,53727,459
Total other revenue--------
Total revenue28,45229,57227,53727,459
Gross profit24,20124,65423,55123,414
Total cost of revenue4,2514,9183,9864,045
Total operating expense14,96218,36615,11714,962
Selling / general / administrative7,7009,0757,8757,740
Research & development3,2894,4703,4583,331
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----00
Other operating expenses, total-278-97-202-154
Operating income13,49011,20612,42012,497
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax13,00410,94212,30112,602
Income after tax10,1568,6999,8039,968
Income tax, total2,8482,2432,4982,634
Net income10,1568,6999,8039,968
Total adjustments to net income--------
Net income before extra. items10,1568,6999,8039,968
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items10,1568,6999,8039,968
Inc. avail. to common incl. extra. items10,1568,6999,8039,968
Diluted net income10,1568,6999,8039,968
Dilution adjustment00--0
Diluted weighted average shares2,5002,5172,5312,541
Diluted EPS excluding extraordinary itemsvalue per share4.063.463.873.92
Dividends per sharevalue per share0.006.770.000.00
Diluted normalized EPSvalue per share4.063.463.873.92